Third dose of BNT162b2 improves immune response in liver transplant recipients to ancestral strain but not Omicron BA.1 and XBB
Vaccine immunogenicity in transplant recipients can be impacted by the immunosuppressive (IS) regimens they receive. While BNT162b2 vaccination has been shown to induce an immune response in liver transplant recipients (LTRs), it remains unclear how different IS regimens may affect vaccine immunogen...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Other Authors: | |
| Format: | Journal Article |
| Language: | English |
| Published: |
2023
|
| Subjects: | |
| Online Access: | https://hdl.handle.net/10356/171510 |
| _version_ | 1826114925491126272 |
|---|---|
| author | Chang, Zi Wei Goh, Yun Shan Rouers, Angeline Fong, Siew-Wai Tay, Matthew Zirui Chavatte, Jean-Marc Hor, Pei Xiang Loh, Chiew Yee Huang, Yuling Tan, Yong Jie Neo, Vanessa Kam, Isaac Kai Jie Yeo, Nicholas Kim-Wah Tan, Eunice X. Huang, Daniel Wang, Bei Siti Nazihah Mohd Salleh Ngoh, Eve Zi Xian Wang, Cheng-I Leo, Yee-Sin Lin, Raymond Tzer Pin Lye, David C. Young, Barnaby Edward Muthiah, Mark Ng, Lisa F. P. Rénia, Laurent |
| author2 | Lee Kong Chian School of Medicine (LKCMedicine) |
| author_facet | Lee Kong Chian School of Medicine (LKCMedicine) Chang, Zi Wei Goh, Yun Shan Rouers, Angeline Fong, Siew-Wai Tay, Matthew Zirui Chavatte, Jean-Marc Hor, Pei Xiang Loh, Chiew Yee Huang, Yuling Tan, Yong Jie Neo, Vanessa Kam, Isaac Kai Jie Yeo, Nicholas Kim-Wah Tan, Eunice X. Huang, Daniel Wang, Bei Siti Nazihah Mohd Salleh Ngoh, Eve Zi Xian Wang, Cheng-I Leo, Yee-Sin Lin, Raymond Tzer Pin Lye, David C. Young, Barnaby Edward Muthiah, Mark Ng, Lisa F. P. Rénia, Laurent |
| author_sort | Chang, Zi Wei |
| collection | NTU |
| description | Vaccine immunogenicity in transplant recipients can be impacted by the immunosuppressive (IS) regimens they receive. While BNT162b2 vaccination has been shown to induce an immune response in liver transplant recipients (LTRs), it remains unclear how different IS regimens may affect vaccine immunogenicity after a third BNT162b2 dose in LTRs, which is especially important given the emergence of the Omicron sublineages of SARS-CoV-2. A total of 95 LTRs receiving single and multiple IS regimens were recruited and offered three doses of BNT162b2 during the study period. Blood samples were collected on days 0, 90, and 180 after the first BNT162b2 dose. At each time point, levels of anti-spike antibodies, their neutralizing activity, and specific memory B and T cell responses were assessed. LTRs receiving single IS regimens showed an absence of poor immunogenicity, while LTRs receiving multiple IS regimens showed lower levels of spike-specific antibodies and immunological memory compared to vaccinated healthy controls after two doses of BNT162b2. With a third dose of BNT162b2, spike-specific humoral, memory B, and T cell responses in LTR significantly improved against the ancestral strain of SARS-CoV-2 and were comparable to those seen in healthy controls who received only two doses of BNT162b2. However, LTRs receiving multiple IS regimens still showed poor antibody responses against Omicron sublineages BA.1 and XBB. A third dose of BNT162b2 may be beneficial in boosting antibody, memory B, and T cell responses in LTRs receiving multiple IS regimens, especially against the ancestral Wuhan strain of SARS-CoV-2. However, due to the continued vulnerability of LTRs to presently circulating Omicron variants, antiviral treatments such as medications need to be considered to prevent severe COVID-19 in these individuals. |
| first_indexed | 2024-10-01T03:47:10Z |
| format | Journal Article |
| id | ntu-10356/171510 |
| institution | Nanyang Technological University |
| language | English |
| last_indexed | 2024-10-01T03:47:10Z |
| publishDate | 2023 |
| record_format | dspace |
| spelling | ntu-10356/1715102023-11-05T15:39:18Z Third dose of BNT162b2 improves immune response in liver transplant recipients to ancestral strain but not Omicron BA.1 and XBB Chang, Zi Wei Goh, Yun Shan Rouers, Angeline Fong, Siew-Wai Tay, Matthew Zirui Chavatte, Jean-Marc Hor, Pei Xiang Loh, Chiew Yee Huang, Yuling Tan, Yong Jie Neo, Vanessa Kam, Isaac Kai Jie Yeo, Nicholas Kim-Wah Tan, Eunice X. Huang, Daniel Wang, Bei Siti Nazihah Mohd Salleh Ngoh, Eve Zi Xian Wang, Cheng-I Leo, Yee-Sin Lin, Raymond Tzer Pin Lye, David C. Young, Barnaby Edward Muthiah, Mark Ng, Lisa F. P. Rénia, Laurent Lee Kong Chian School of Medicine (LKCMedicine) School of Biological Sciences National Centre for Infectious Diseases Tan Tock Seng Hospital Infectious Diseases Labs, A*STAR National University of Singapore Science::Medicine SARS-CoV-2 Spike Protein Vaccine immunogenicity in transplant recipients can be impacted by the immunosuppressive (IS) regimens they receive. While BNT162b2 vaccination has been shown to induce an immune response in liver transplant recipients (LTRs), it remains unclear how different IS regimens may affect vaccine immunogenicity after a third BNT162b2 dose in LTRs, which is especially important given the emergence of the Omicron sublineages of SARS-CoV-2. A total of 95 LTRs receiving single and multiple IS regimens were recruited and offered three doses of BNT162b2 during the study period. Blood samples were collected on days 0, 90, and 180 after the first BNT162b2 dose. At each time point, levels of anti-spike antibodies, their neutralizing activity, and specific memory B and T cell responses were assessed. LTRs receiving single IS regimens showed an absence of poor immunogenicity, while LTRs receiving multiple IS regimens showed lower levels of spike-specific antibodies and immunological memory compared to vaccinated healthy controls after two doses of BNT162b2. With a third dose of BNT162b2, spike-specific humoral, memory B, and T cell responses in LTR significantly improved against the ancestral strain of SARS-CoV-2 and were comparable to those seen in healthy controls who received only two doses of BNT162b2. However, LTRs receiving multiple IS regimens still showed poor antibody responses against Omicron sublineages BA.1 and XBB. A third dose of BNT162b2 may be beneficial in boosting antibody, memory B, and T cell responses in LTRs receiving multiple IS regimens, especially against the ancestral Wuhan strain of SARS-CoV-2. However, due to the continued vulnerability of LTRs to presently circulating Omicron variants, antiviral treatments such as medications need to be considered to prevent severe COVID-19 in these individuals. Agency for Science, Technology and Research (A*STAR) Ministry of Education (MOE) National Medical Research Council (NMRC) Published version This work was supported by the Biomedical Research Council (BMRC), A*CRUSE (Vaccine monitoring project), the A*ccelerate GAP-funded project (ACCL/19-GAP064-R20H-H) from the Agency of Science, Technology and Research (A*STAR), Singapore National Medical Research Council COVID-19 Research Fund (COVID19RF001; COVID19RF-007; COVID19RF-011; COVID19RF-0008; COVID19RF-060), and A*STAR COVID-19 Research funding (H/ 20/04/g1/006). LR was also supported by a Start-up University Grant from Ministry of Education (SUJ #022388-00001). 2023-10-30T01:38:55Z 2023-10-30T01:38:55Z 2023 Journal Article Chang, Z. W., Goh, Y. S., Rouers, A., Fong, S., Tay, M. Z., Chavatte, J., Hor, P. X., Loh, C. Y., Huang, Y., Tan, Y. J., Neo, V., Kam, I. K. J., Yeo, N. K., Tan, E. X., Huang, D., Wang, B., Siti Nazihah Mohd Salleh, Ngoh, E. Z. X., Wang, C., ...Rénia, L. (2023). Third dose of BNT162b2 improves immune response in liver transplant recipients to ancestral strain but not Omicron BA.1 and XBB. Frontiers in Immunology, 14, 1206016-. https://dx.doi.org/10.3389/fimmu.2023.1206016 1664-3224 https://hdl.handle.net/10356/171510 10.3389/fimmu.2023.1206016 37465685 2-s2.0-85165023675 14 1206016 en ACCL/19-GAP064-R20H-H COVID19RF-001 COVID19RF-007 COVID19RF-011 COVID19RF-0008 COVID19RF-060 H/20/04/g1/006 SUJ #022388-00001 Frontiers in Immunology © 2023 Chang, Goh, Rouers, Fong, Tay, Chavatte, Hor, Loh, Huang, Tan, Neo, Kam, Yeo, Tan, Huang, Wang, Salleh, Ngoh, Wang, Leo, Lin, Lye, Young, Muthiah, Ng, Renia and COVID-19 Study Group. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. application/pdf |
| spellingShingle | Science::Medicine SARS-CoV-2 Spike Protein Chang, Zi Wei Goh, Yun Shan Rouers, Angeline Fong, Siew-Wai Tay, Matthew Zirui Chavatte, Jean-Marc Hor, Pei Xiang Loh, Chiew Yee Huang, Yuling Tan, Yong Jie Neo, Vanessa Kam, Isaac Kai Jie Yeo, Nicholas Kim-Wah Tan, Eunice X. Huang, Daniel Wang, Bei Siti Nazihah Mohd Salleh Ngoh, Eve Zi Xian Wang, Cheng-I Leo, Yee-Sin Lin, Raymond Tzer Pin Lye, David C. Young, Barnaby Edward Muthiah, Mark Ng, Lisa F. P. Rénia, Laurent Third dose of BNT162b2 improves immune response in liver transplant recipients to ancestral strain but not Omicron BA.1 and XBB |
| title | Third dose of BNT162b2 improves immune response in liver transplant recipients to ancestral strain but not Omicron BA.1 and XBB |
| title_full | Third dose of BNT162b2 improves immune response in liver transplant recipients to ancestral strain but not Omicron BA.1 and XBB |
| title_fullStr | Third dose of BNT162b2 improves immune response in liver transplant recipients to ancestral strain but not Omicron BA.1 and XBB |
| title_full_unstemmed | Third dose of BNT162b2 improves immune response in liver transplant recipients to ancestral strain but not Omicron BA.1 and XBB |
| title_short | Third dose of BNT162b2 improves immune response in liver transplant recipients to ancestral strain but not Omicron BA.1 and XBB |
| title_sort | third dose of bnt162b2 improves immune response in liver transplant recipients to ancestral strain but not omicron ba 1 and xbb |
| topic | Science::Medicine SARS-CoV-2 Spike Protein |
| url | https://hdl.handle.net/10356/171510 |
| work_keys_str_mv | AT changziwei thirddoseofbnt162b2improvesimmuneresponseinlivertransplantrecipientstoancestralstrainbutnotomicronba1andxbb AT gohyunshan thirddoseofbnt162b2improvesimmuneresponseinlivertransplantrecipientstoancestralstrainbutnotomicronba1andxbb AT rouersangeline thirddoseofbnt162b2improvesimmuneresponseinlivertransplantrecipientstoancestralstrainbutnotomicronba1andxbb AT fongsiewwai thirddoseofbnt162b2improvesimmuneresponseinlivertransplantrecipientstoancestralstrainbutnotomicronba1andxbb AT taymatthewzirui thirddoseofbnt162b2improvesimmuneresponseinlivertransplantrecipientstoancestralstrainbutnotomicronba1andxbb AT chavattejeanmarc thirddoseofbnt162b2improvesimmuneresponseinlivertransplantrecipientstoancestralstrainbutnotomicronba1andxbb AT horpeixiang thirddoseofbnt162b2improvesimmuneresponseinlivertransplantrecipientstoancestralstrainbutnotomicronba1andxbb AT lohchiewyee thirddoseofbnt162b2improvesimmuneresponseinlivertransplantrecipientstoancestralstrainbutnotomicronba1andxbb AT huangyuling thirddoseofbnt162b2improvesimmuneresponseinlivertransplantrecipientstoancestralstrainbutnotomicronba1andxbb AT tanyongjie thirddoseofbnt162b2improvesimmuneresponseinlivertransplantrecipientstoancestralstrainbutnotomicronba1andxbb AT neovanessa thirddoseofbnt162b2improvesimmuneresponseinlivertransplantrecipientstoancestralstrainbutnotomicronba1andxbb AT kamisaackaijie thirddoseofbnt162b2improvesimmuneresponseinlivertransplantrecipientstoancestralstrainbutnotomicronba1andxbb AT yeonicholaskimwah thirddoseofbnt162b2improvesimmuneresponseinlivertransplantrecipientstoancestralstrainbutnotomicronba1andxbb AT taneunicex thirddoseofbnt162b2improvesimmuneresponseinlivertransplantrecipientstoancestralstrainbutnotomicronba1andxbb AT huangdaniel thirddoseofbnt162b2improvesimmuneresponseinlivertransplantrecipientstoancestralstrainbutnotomicronba1andxbb AT wangbei thirddoseofbnt162b2improvesimmuneresponseinlivertransplantrecipientstoancestralstrainbutnotomicronba1andxbb AT sitinazihahmohdsalleh thirddoseofbnt162b2improvesimmuneresponseinlivertransplantrecipientstoancestralstrainbutnotomicronba1andxbb AT ngohevezixian thirddoseofbnt162b2improvesimmuneresponseinlivertransplantrecipientstoancestralstrainbutnotomicronba1andxbb AT wangchengi thirddoseofbnt162b2improvesimmuneresponseinlivertransplantrecipientstoancestralstrainbutnotomicronba1andxbb AT leoyeesin thirddoseofbnt162b2improvesimmuneresponseinlivertransplantrecipientstoancestralstrainbutnotomicronba1andxbb AT linraymondtzerpin thirddoseofbnt162b2improvesimmuneresponseinlivertransplantrecipientstoancestralstrainbutnotomicronba1andxbb AT lyedavidc thirddoseofbnt162b2improvesimmuneresponseinlivertransplantrecipientstoancestralstrainbutnotomicronba1andxbb AT youngbarnabyedward thirddoseofbnt162b2improvesimmuneresponseinlivertransplantrecipientstoancestralstrainbutnotomicronba1andxbb AT muthiahmark thirddoseofbnt162b2improvesimmuneresponseinlivertransplantrecipientstoancestralstrainbutnotomicronba1andxbb AT nglisafp thirddoseofbnt162b2improvesimmuneresponseinlivertransplantrecipientstoancestralstrainbutnotomicronba1andxbb AT renialaurent thirddoseofbnt162b2improvesimmuneresponseinlivertransplantrecipientstoancestralstrainbutnotomicronba1andxbb |